EXCLUSIVE: The latest figures are all too clear: we are in the middle of an epidemic of diabetes.

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Cynata Therapeutics Limited ( OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ET Lauren Nowak - Media Relations Kilian Kelly - Chief Executive Officer and Managing Director ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Novo Nordisk estimates that around 40% of people with type 2 diabetes have chronic kidney disease, which affects about 37 million adults in the United States. Last year, the FDA had approved the ...